Denosumab antibody | AbD26295_hIgG1

100% Secure


Human anti Denosumab:HRP

Anti-denosumab antibody is a recombinant, inhibitory, anti-idiotypic antibody in IgG1 format for use in bioanalytical assays to measure denosumab and biosimilars. It can be used as detection antibody in a PK bridging ELISA with HCA288, and as reference standard in an ADA bridging ELISA.

Human anti Denosumab

Anti-denosumab antibody is a recombinant, inhibitory, anti-idiotypic antibody in IgG1 format for use in bioanalytical assays to measure denosumab and biosimilars. It can be used as detection antibody in a PK bridging ELISA with HCA288, and as reference standard in an ADA bridging ELISA.

Product Type
Monoclonal Antibody
Clone
AbD26295_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA280P E 0.1 mg
HCA280 E 0.1 mg
Human Anti-Denosumab Antibody, clone AbD26295_hIgG1 is a paratope specific anti-idiotypic antibody that specifically recognizes the free human monoclonal antibody denosumab. The antibody does not recognize free RANKL (receptor activator of nuclear factor kappa-B ligand) or denosumab in complex with human RANKL and can be used to measure free denosumab and biosimilar products.

Clone AbD26295_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay.

A pair of anti denosumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in full immunoglobulin format, is recommended as the detection antibody paired with clone AbD26296 (HCA288) in monovalent Fab format as the capture antibody.

Denosumab (Prolia, Xgeva) is a fully human monoclonal antibody (IgG2/kappa) for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone. The drug specifically binds to human RANKL a protein that acts as the primary signal to promote bone removal/resorption and prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors.

View a summary of all anti-denosumab antibodies.

Product Details

Product Form
Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) – liquid
Product Form
Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line - liquid
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Denosumab
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD=1.8 nM by real time, label-free molecular interaction analysis on immobilized denosumab
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.5 mg/ml

Storage Information

Storage
Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use
Shelf Life
12 months from date of despatch
Shelf Life
12 months from date of despatch

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Prolia and Xgeva are registered trademarks of Amgen Inc.
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Prolia and Xgeva are registered trademarks of Amgen Inc.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad
Regulatory
For research purposes only

Applications of Denosumab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used in a direct ELISA or as a detection antibody in a bridging ELISA together with HCA288 (AbD26296) as the capture reagent.
Protocol: PK bridging ELISA to measure total drug
ELISA
This product may be used in direct or indirect ELISA and in an ELISA bridging assay as a detection antibody together, when conjugated to HRP, with HCA288 as the capture reagent. It is also suitable as a fully human control or calibrator antibody in an ADA bridging ELISA.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Human anti Denosumab HCA281 0.1 mg E
Human anti Denosumab HCA282 0.1 mg E
Human anti Denosumab HCA288 0.1 mg E
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Denosumab:HRP HCA280P 0.1 mg E
Human anti Denosumab HCA281 0.1 mg E
Human anti Denosumab HCA282 0.1 mg E
Human anti Denosumab HCA288 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK001P 1 Conjugation For 400µg Antibody CJ